In re Solodyn (Minocycline Hydrochloride) Antitrust Litigation
Berger Montague served as co-lead counsel representing a class of direct purchasers of brand and generic Solodyn (extended-release minocycline hydrochloride tablets) alleging that Medicis Pharmaceutical Corp. entered into agreements with each of Impax Laboratories, Inc., Sandoz Inc. and Lupin Limited/Lupin Pharmaceuticals, Inc. not to compete in the market for extended-release minocycline hydrochloride tablets, i.e., Solodyn and its generic equivalents, in violation of the Sherman Act, resulting in the class paying overcharge damages.
After more than four years of litigation and on the eve of trial, the direct purchaser class settled with the last remaining defendant, Impax Laboratories, Inc. In total, the Class received more than $76 million in settlements. Each of the settlements has been preliminarily approved, and the final approval hearing for the last two settlements is scheduled for July 18, 2018.
LEAD ATTORNEYS: David F. Sorensen, Andrew C. Curley, Caitlin G. Costlett